mRNA profiling after knockdown of Circular RNA-INSR

The recent advances in anti-cancer treatments have led to a steady increase in the number of cancer survivors, paradoxically also enhancing the number of HF patients who suffer from the undesired cardiotoxic side effects of these anti-tumor treatments. Therapeutic options to reduce or reverse chemotherapy-induced HF are not available. Circular RNAs exhibit high druggability due to the high stability of their special closed loop structure. Circ-INSR overexpression prevents doxorubicin-induced cardiac dysfunction in preclinical murine and human models. Circ-INSR mimics produced in vitro also reduced cardiomyocyte death under doxorubicin stress, highlighting the potential of Circ-INSR-based RNA therapy for future clinical applications. Overall design: HL-1 cells were treated with100 nM Circ-INSR siRNA and Scramble siRNA. Total RNA was harvested, sequencing was performed in triplicates.